LLS targets acute myeloid leukemia in new collaborative clinical trial
+ Technology/Innovation
Mark Iandolo | Oct 23, 2016

LLS targets acute myeloid leukemia in new collaborative clinical trial

The Leukemia and Lymphoma Society (LLS) recently launched a collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease for which treatments have not improved much in the last four decades.

 

Vice President Joe Biden announced Beat AML, as the initiative is called, along with several other initiatives as part of Cancer Moonshot.

 

AML is the most dangerous of all blood cancers -- responsible for more than 10,000 deaths every year. As a group, blood cancers are the third leading cause of cancer deaths in the U.S. Improvements in treating AML have stagnated, and the five-year survival rate is below 20 percent for patients over 60.

 

“The Leukemia and Lymphoma Society is uniquely qualified to lead this unprecedented clinical trial collaboration, rare for a nonprofit and a first for LLS,” Louis DeGennaro, LLS president and CEO, said. “Beat AML, as we have named this master trial, showcases LLS’s stature in the cancer ecosystem. It demonstrates our ability to convene the medical and research communities to think and act boldly in the quest for new and better treatments for blood cancer patients, and our aim to accelerate the rate at which precisely targeted breakthrough therapies reach the patients who urgently need them.”

Organizations in this story

More News